These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23874575)

  • 21. Directly administered antiretroviral therapy: pilot study of a structural intervention in methadone maintenance.
    Sorensen JL; Haug NA; Larios S; Gruber VA; Tulsky J; Powelson E; Logan DP; Shapiro B
    J Subst Abuse Treat; 2012 Dec; 43(4):418-23. PubMed ID: 23007110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.
    ENCORE1 Study Group
    Lancet; 2014 Apr; 383(9927):1474-1482. PubMed ID: 24522178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial.
    Agwu AL; Warshaw MG; McFarland EJ; Siberry GK; Melvin AJ; Wiznia AA; Fairlie L; Boyd S; Harding P; Spiegel HML; Abrams EJ; Carey VJ;
    PLoS One; 2017; 12(6):e0178075. PubMed ID: 28604824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics.
    Berg KM; Mouriz J; Li X; Duggan E; Goldberg U; Arnsten JH
    Contemp Clin Trials; 2009 Sep; 30(5):481-9. PubMed ID: 19505589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization.
    Sansom SL; Anthony MN; Garland WH; Squires KE; Witt MD; Kovacs Andrea A; Larsen RA; Valencia R; Pals SL; Hader S; Weidle PJ; Wohl AR
    AIDS Patient Care STDS; 2008 Feb; 22(2):131-8. PubMed ID: 18260804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
    Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
    J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positive STEPS - a randomized controlled efficacy trial of an adaptive intervention for strengthening adherence to antiretroviral HIV treatment among youth: study protocol.
    Mimiaga MJ; Kuhns LM; Biello KB; Olson J; Hoehnle S; Santostefano CM; Hughto JMW; Safi H; Salhaney P; Chen D; Garofalo R
    BMC Public Health; 2018 Jul; 18(1):867. PubMed ID: 30001703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medication persistence of HIV-infected drug users on directly administered antiretroviral therapy.
    Ing EC; Bae JW; Maru DS; Altice FL
    AIDS Behav; 2013 Jan; 17(1):113-21. PubMed ID: 22105340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention.
    Berg KM; Litwin AH; Li X; Heo M; Arnsten JH
    Clin Infect Dis; 2011 Nov; 53(9):936-43. PubMed ID: 21890753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load.
    Kibalama Ssemambo P; Nalubega-Mboowa MG; Owora A; Serunjogi R; Kironde S; Nakabuye S; Ssozi F; Nannyonga M; Musoke P; Barlow-Mosha L
    BMC Pediatr; 2021 Mar; 21(1):139. PubMed ID: 33752636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attitudes toward directly administered antiretroviral therapy (DAART) among HIV-positive inpatients in an inner city public hospital.
    Santos CQ; Adeyemi O; Tenorio AR
    AIDS Care; 2006 Oct; 18(7):808-11. PubMed ID: 16971292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
    JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
    Fabbiani M; Gagliardini R; Ciccarelli N; Quiros Roldan E; Latini A; d'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Del Pin B; Lombardi F; D'Avino A; Focà E; Colafigli M; Cauda R; Di Giambenedetto S; De Luca A;
    J Antimicrob Chemother; 2018 Jul; 73(7):1955-1964. PubMed ID: 29668978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
    Gianotti N; Lorenzini P; Cozzi-Lepri A; De Luca A; Madeddu G; Sighinolfi L; Pinnetti C; Santoro C; Meraviglia P; Mussini C; Antinori A; d'Arminio Monforte A;
    J Antimicrob Chemother; 2019 Sep; 74(9):2732-2741. PubMed ID: 31173639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.